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Abstract
Aim: Combined hepatocellular cholangiocarcinoma (combined tumor) has been described as either a variant of hepatoma 
or a variant of cholangiocarcinoma. Prior studies evaluated fewer than 50 patients with combined tumors, precluding mul-
tivariate analyses. Posited was the notion that analysis of a large database would yield more deﬁ  nite answers.
Methods: This study used SEER (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) 
to analyze 282 combined tumors, 2,035 intrahepatic cholangiocarcinomas, and 19,336 hepatomas between the years 
1973–2003. Multinomial logit regression calculated point estimates and 95% conﬁ  dence intervals (c.i.) for relative risk (rr). 
Cox regression calculated point estimates and 95% conﬁ  dence intervals (c.i.) for hazard ratios (ĥ).
Results: Men less often had cholangiocarcinomas than they had combined tumors (rr = 0.63, c.i. = 0.49–0.81). Hepatomas 
less often than combined tumors presented with distant spread (rr = 0.56, c.i. = 0.43–0.72). Men (rr = 1.50, c.i. = 1.17–1.93) 
and patients with a known Asian or Paciﬁ  c birthplace (rr = 2.36, c.i. = 1.56–3.56) more often had hepatomas than they had 
combined tumors. Among patients not known to have an Asian/Paciﬁ  c birthplace, a diagnosis of cholangiocarcinoma 
(ĥ = 0.72, c.i. = 0.63–0.82) or hepatoma (ĥ = 0.75, c.i. = 0.66–0.86) provided a better prognosis than did a diagnosis of 
combined tumor.
Conclusion: Combined tumors differ from hepatomas and cholangiocarcinomas in terms of distribution and survival patterns 
in the population; they should be considered neither cholangiocarcinomas nor hepatomas.
Keywords: hepatoma, cholangiocarcinoma, combined hepatocellular cholangiocarcinoma, multinomial logit, survival 
analysis
Introduction
Combined hepatocellular cholangiocarcinomas (combined tumors) have been a source of controversy 
ever since they were described [Allen, 1949]. Multiple studies have been performed [Liver Cancer Study 
Group of Japan, 1990; Maeda, 1995; Ng, 1998; Jarnagin, 2002; Tickoo, 2002; Tang, 2006], none with 
more than 50 patients with combined tumors. Some thought combined tumor a form of intrahepatic 
cholangiocarcinoma [Jarnagin, 2002; Tickoo, 2002]; others felt it to be a variant of hepatoma [Maeda, 
1995; Ng, 1998; Tang, 2006]. The Surveillance, Epidemiology, and End Results (SEER) Program of the 
National Cancer Institute has been found to be an authoritative source of information on cancer incidence 
and survival in the United States; information concerning this database has been made available at its 
website (www.seer.com). Posited was the notion that this large database would provide enough patients 
for multivariate analyses that might better deﬁ  ne combined tumors. Assessed were the contributions of 
gender, stage, age, and place of birth to the distribution of the tumor types. Also evaluated were survival 
differences among tumor types after gender, place of birth, stage, and age were accounted for.
Materials and Methods
A case listing session provided patients from the SEER 17 Registry data base over the period 1973–2003. 
Table 1 displayed inclusion and exclusion criteria and the means by which patient subgroups were 44
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created. R 2.5.1 analyzed the data. χ² tests assessed 
relationships of tumor type and 1) age, 2) stage, 3) 
birthplace, and 4) gender. Multinomial logit regres-
sion compared 1) cholangiocarcinoma and com-
bined tumors and 2) hepatoma and combined 
tumors with respect to age, stage, birthplace, and 
gender. The Hausmann test assessed the indepen-
dence of irrelevant alternatives assumption. The 
Kaplan-Meier method yielded survival estimates. 
Log rank tests and Cox regression analyzed sur-
vival differences. The Grambsch-Therneau test 
assessed the proportional hazards assumption. 
Because frequency and survival analyses were 
performed, a Bonferroni adjustment was made; null 
hypotheses were rejected when P  0.025.
Results
Table 2 displayed frequency distributions for the 
22,553 patients. 282 (1.3%) had combined tumors. 
2,935 (13.0%) had intrahepatic cholangiocarcinomas. 
19,336 (85.7%) had hepatomas. 13,268 (58.8%) 
lacked distant spread. 5,482 (24.3%) showed 
distant spread. 6,582 (29.2%) were women. 3,895 
(17.3%) had a known Asian/Paciﬁ  c birthplace. χ² 
tests showed tumor types differed as regards stage, 
gender, birthplace, and age (P  0.025, for each 
analysis).
Multinomial logit regression (Table 3) yielded 
point estimates and 95% conﬁ  dence intervals (c.i.) 
for relative risk (rr). Men were less likely than 
women (rr = 0.63, c.i. = 0.49–0.81) to develop 
cholangiocarcinomas than combined tumors. Men 
more than women (rr = 1.50, 95% c.i. = 1.17–1.93) 
and patients with known Asian/Paciﬁ  c birthplaces 
more than those born elsewhere (rr = 2.36, c.i. = 
1.56–3.56) more likely had hepatomas than 
combined tumors. Hepatomas were less likely to 
present with distant spread than were combined 
tumors (rr = 0.56, c.i. = 0.43–0.72).
The Hausmann test was performed. Point esti-
mate vectors for models with (pf) and without (ps) 
cholangiocarcinoma were calculated. Removal of 
pf elements related to cholangiocarcinoma yielded 
a conformable vector (pfc). The difference vector 
(d) was d = ps–pfc. Variance-covariance matrixes 
for models with (Cf) and without (Cs) cholangio-
carcinoma were calculated. Removal of Cf 
Table 1. Data acquisition schema.
Database
SEER 17 Regs Public-Use, Nov 2005 (1973–2003 
varying)
Selection criteria
Site: Liver and intrahepatic bile duct
Limited to histologic type:
 Cholangiocarcinoma—ICD-0  8160
 Hepatoma—ICD-0  8170
 Combined  tumor—ICD-0  8180
Follow-up: Active
First malignant primary indicator: Yes
Diagnostic conﬁ  rmation: Microscopically conﬁ  rmed
Excluded: Autopsy/Death certiﬁ  cate cases
Data collected and stratiﬁ  cation
Gender
Age at diagnosis: Below median of 65 years and 65 
or more years
Stage: No metastases, unstaged, and metastases
Place of birth: Asian/Paciﬁ  c and other
Survival time in months: Up to 48 months
Vital status
Table 2. Frequency distributions (and percents) of 22,553 patients with liver tumors by histologic type with respect 
to stage, gender, birthplace, and age. For each variables, χ² tests showed the differences with respect to tumor 
type could not have been explained by chance (P  0.025).
 Combined  tumors  Cholangiocarcinomas  Hepatomas  Total
Stage      
  No metastases  147 (1.1%)  1,376 (10.4%)  11,745 (88.5%)  13,268 (100%)
  Unstaged  37 (1.0%)  505 (13.3%)  3,261 (85.7%)  3,803 (100%)
  Metastases  98 (1.8%)  1,054 (19.2%)  4,330 (79.0%)  5,482 (100%)
Gender      
  Women  98 (1.5%)  1,364 (20.7%)  5,120 (77.8%)  6,582 (100%)
  Men  184 (1.2%)  1,571 (9.8%)  14,216 (89.0%)  15,971 (100%)
Birthplace      
 Asian/Paciﬁ  c  25 (0.6%)  252 (6.5%)  3,618 (92.9%)  3,895 (100%)
  Other  257 (1.4%)  2,683 (14.4%)  15,718 (84.2%)  18,658 (100%)
Age      
  Less than 65 years  146 (1.3%)  1,315 (11.8%)  9709 (86.9%)  11,170 (100%)
  65 or more years  136 (1.2%)  1,620 (14.2%)  9627 (84.6%)  11,383 (100%)45
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elements related to cholangiocarcinoma yielded a 
conformable matrix (Cfc). The difference matrix 
(Q) was Q = Cs–Cfc. Then, χ² = d
TMd, where M 
was the generalized inverse of Q. The degrees of 
freedom (d.f.) was the rank of Q. The indepen-
dence of irrelevant alternatives assumption held 
(χ² = 0.17, 6 d.f., P  0.50).
Univariate survival analyses (Table 4) showed 
median survivals ranging from two to six months; 
log rank tests showed statistically signiﬁ  cant dif-
ferences among tumor types with respect to age, 
stage, birthplace and gender (P  0.025, for each 
analysis). Cox regression (Table 5) calculated haz-
ard ratios (ĥ) and 95% conﬁ  dence intervals (c.i.). 
The Grambsch-Therneau test showed the 
proportional hazards assumption did not hold for 
birthplace (ρ = 0.033; χ² = 20.43, P  0.025); the 
analysis was stratiﬁ  ed by birthplace. Persons with 
a known Asian/Paciﬁ  c birthplace lacked statistically 
signiﬁ  cant predictor variables (P  0.025, for each 
analysis). Among patients without a known Asian/
Paciﬁ  c birthplace, cholangiocarcinomas (ĥ = 0.72, 
Table 3. Multinomial logit regression comparing 2,935 patients with intra-hepatic cholangiocarcinomas and 19,336 
patients with hepatomas with 282 patients with combined tumors.
  β (s.e.)  Z  rr (95% c.i.)
Cholangicarcinoma v. combined tumor   
 Intercept  2.4   
  Man v. woman  −0.46 (0.13)  −3.53* 0.63  (0.49–0.81)
  Unstaged v. no metastases  0.36 (0.19)  1.88  1.43 (0.98–2.09)
  Metastases v. no metastases  0.15 (0.14)  1.11  1.16 (0.89–1.52)
  Asian or Paciﬁ  c birth v. other  0.01 (0.22)  0.03  1.01 (0.65–1.55)
  65 or more years old v. younger  0.21 (0.13)  1.64  1.23 (0.96–1.58)
Hepatoma v. combined tumor   
 Intercept  3.92   
  Man v. woman  0.41 (0.13)  3.19*  1.50 (1.17–1.93)
  Unstaged v. no metastases  0.12 (0.19)  0.65  1.13 (0.78–1.62)
  Metastases v. no metastases  −0.58 (0.13)  −4.43* 0.56  (0.43–0.72)
 Asian/Paciﬁ  c birth v. other  0.86 (0.21)  4.08*  2.36 (1.56–3.56)
  65 or more years old v. younger  0.11 (0.12)  0.94  1.12 (0.88–1.42)
*P  0.025.
Table 4. Univariate survival analyses.
 Patients  Deaths  Median  survival  Log  rank
 n  = 22,553  n = 18,803  Months (95% c.i.)  χ² (df)
Histologic type       
  Combined  282 (1.3%)  254 (1.4%)  3 (2–3) 
  Cholangiocarcinoma  2,935 (13%)  2,568 (13.7%)  4 (4–5) 
  Hepatoma  19,336 (85.7%)  15,981 (85%)  4 (4–4)  34.2 (2)*
Asian or Paciﬁ  c birthplace     
  No  18,658 (82.7%)  15,645 (83.2%)  4 (4–4) 
  Yes  3,895 (17.3%)  3,158 (16.8%)  5 (5–6)  74.4 (1)*
Age in years       
  65 or more  11,170 (49.5%)  8,872 (47.2%)  5 (4–5) 
  64 or less  11,383 (50.5%)  9,931 (52.8%)  3 (3–4)  234 (1)*
Gender      
  Woman  6,582 (29.2%)  5,435 (28.9%)  5 (4–5) 
  Man  15,971 (70.8%)  13,368 (71.1%)  4 (4–4)  43.8 (1)*
Metastatic status       
  No metastases  13,268 (58.8%)  10,188 (54.2%)  6 (6–6) 
  Unstaged  3,803 (16.9%)  3,463 (18.4%)  3 (3–3) 
  Metastases  5,482 (24.3%)  5,152 (27.4%)  2 (2–2)  1,991 (2)*
*P  0.025.46
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c.i. = 0.63–0.82) and hepatomas (ĥ = 0.75, 
c.i. = 0.66–0.86) imparted a better prognosis than 
did combined tumors.
Discussion
This study compared combined tumors with 
cholangiocarcinomas and hepatomas. For men more 
than for women, cholangiocarcinomas were less 
often seen than were combined tumors. Hepatomas, 
more so than combined tumors, were seen in men 
(relative to women), presented without distant spread 
(relative to presenting without distant spread), and 
arose in patients with an Asian/Paciﬁ  c birthplace 
(relative to those born elsewhere). Among those with 
a non-Asian/Paciﬁ  c birthplace, a diagnosis of chol-
angiocarcinoma or hepatomas conferred a better 
prognosis than did a diagnosis of combined tumor.
Both hepatitis B and hepatitis C have been found 
to induce hepatoma [Engstrom, 2003]; recent studies 
have also implicated both viruses with respect to 
cholangiocarcinoma [Gatselis, 2007; Hai, 2005; 
Perumal, 2006; Shaib, 2007]. The pre-S mutant of 
hepatitis B has been shown to most often be seen in 
those parts of the world (Asia and the Paciﬁ  c) that 
have high rates of hepatoma; a relationship to chol-
angiocarcinoma has not been found [Fan y, 2001; 
Huy TT, 2003]. This study in part conﬁ  rmed these 
results by comparing patients with a known Asian/
Paciﬁ  c birthplace to those without a known Asian/
Paciﬁ  c birthplace. Hepatomas, but not cholangiocar-
cinomas, were more often seen in persons with an 
Asian/Paciﬁ  c birthplace than were combined tumors, 
when compared with patients born elsewhere.
Limitations of this study included its inability 
to subclassify combined tumors [Goodman, 1985], 
to take into account the results of hepatitis virus 
serologic studies, and to evaluate the effect of 
alcohol and/or drug abuse. The limitations were 
more than compensated for by the increased 
sample size; no prior study of this problem included 
more than 50 patients, precluding multivariate 
analyses. The importance of sample size was 
reﬂ  ected in this study, which had only 25 combined 
tumors in patients with an Asian/Paciﬁ  c birthplace: 
no survival differences with respect to tumor type 
were identiﬁ  ed among this cohort.
The ﬁ  ndings of this study complemented those 
of a recent summary of laboratory ﬁ  ndings. Hepatic 
progenitor cells can have been shown to be able to 
differentiate towards the biliary and hepatocyte 
lineages [Libbrecht, 2006]. The cells have been 
found to be the source of combined tumors. Most 
hepatomas, by contrast, have been shown to derive 
from other cells [Libbrecht, 2006]. Cholangiocar-
cinomas have not been found to have an origin 
from these cells [Libbrecht, 2006]. Some animal 
models suggested a common origin for all three 
tumors, but this has not been demonstrated in 
humans [Libbrecht, 2006]. Irrespective of these 
ﬁ  ndings with respect to tumor classiﬁ  cation, this 
study showed that the differences matter little from 
the patient’s perspective because median survival 
for all three tumor types is less than six months.
This study showed that combined tumors differ 
from hepatomas and cholangiocarcinomas in terms 
of distribution and survival patterns in the 
Table 5. Cox regression analyses.
  β (s.e.)  z  ĥ (95% c.i.)
Asian or Paciﬁ  c birthplace (n = 3895)   
  Cholangiocarcinoma v. combined  −0.25 (0.22)  −1.11 0.78  (0.51–1.2)
  Hepatoma v. combined  −0.28 (0.21)  −1.34 0.76  (0.5–1.14)
  65 or more years v. younger  0.05 (0.04)  1.37  1.05 (0.98–1.13)
  Man v. woman  0.14 (0.04)  3.42*  1.15 (1.06–1.25)
  Unstaged v. no metastases  0.45 (0.05)  8.51*  1.57 (1.41–1.74)
  Metastases v. no metastases  0.79 (0.04)  18.36*  2.21 (2.03–2.4)
Other birthplace (n = 18658)   
  Cholangiocarcinoma v. combined  −0.33 (0.07)  −4.83* 0.72  (0.63–0.82)
  Hepatoma v. combined  −0.28 (0.07)  −4.28* 0.75  (0.66–0.86)
  65 or more years v. younger  0.26 (0.02)  16.24*  1.3 (1.26–1.34)
  Man v. woman  0.14 (0.02)  7.8*  1.15 (1.11–1.19)
  Unstaged v. no metastases  0.41 (0.02)  19.16*  1.51 (1.45–1.57)
  Metastases v. no metastases  0.74 (0.02)  38.71*  2.1 (2.03–2.18)
*P  0.025.47
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population; they should be considered neither 
hepatomas or cholangiocarcinomas.
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